Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 09/10/2014

Meeting Posters

PD
Target(s)
Method Title Year Meeting
MET Immunoassay MET Target Inhibition-Guided Efficacy in Preclinical Models 2014 AACR
DNMT1 Immunoassay Pre-clinical Development of 4'-thio-2'-deoxycytidine (TdCyd) as a DNA-demethylating Agent for Use in Treating Solid Tissue Tumors 2014 AACR
CTCs ApoStream® Isolation and Characterization of Circulating Tumor Cells (CTCs) from Peripheral Blood Specimens of Patients with Advanced Solid Tumor Malignancies (Using ApoStream® Instrumentation) 2014 AACR
MET, EMT Immunofluorescence assay Quantitative immunofluorescence assessment of MET and epithelial-to-mesenchymal transition (EMT) biomarker modulation by antiangiogenic inhibitors in xenograft tumor tissues 2014 AACR
pY15-cdk Immunofluorescence assay Pre-clinical Investigation of the Wee1 Inhibitor, MK-1775, Using Pharmacodynamic and Mechanistic Markers in Diverse Cancer Models In Vivo 2014 AACR
PKM2 Immunoassay Pharmacodynamic Assay for Evaluation of First-In-Class Pyruvate Kinase-M2 Activators in Cancer Tissues 2014 ASCO
QA-QC Immunofluorescence assay Development of Calibrators and Controls as Quality Control Tools for Clinical Implementation of Quantitative Immunofluorescence Assays for Pharmacodynamic Biomarkers of Molecular Targeted Agents in Tumor Biopsies 2013 AACR
QA-QC, HIF1α Immunoassay Creating Clinical Target Validation Groups via Quality-Assured Transfer of Robust Clinical Pharmacodynamic (PD) Assays from the National Cancer Institute: Clinical Implementation of a HIF1α Immunoassay in Tumor Biopsies 2013 AACR
EMT Markers Immunofluorescence assay Development of a Quantitative Immunofluorescence Imaging Assay to Assess β-catenin Translocation and Multiplex Biomarkers for Epithelial-Mesenchymal Transition (EMT) in Tumor Tissues 2013 AACR
Glycolytic Markers Immunoassay Development of a Multiplex Panel of Biomarkers to Assess Energy Metabolism in Cancer 2013 AACR
DNA Damage Response Markers Immunofluorescence assay Development of a Multiplex Quantitative Immunofluorescence Assay to Determine DNA Damage Repair Deficient Models In Vitro and In Vivo and the Response to Cytotoxic Agents 2013 AACR
QA-QC, EMT Markers Immunofluorescence assay Development of Recombinant Transcription Factor Proteins and Antibodies for Application in Clinical Immunoassays 2013 AACR
Apoptosis Markers Immunoassay Progress on Development of a Multiplex Panel of 15 Biomarkers to Support the Development of Anticancer Drugs Targeting Apoptosis 2013 AACR
MET Immunoassay Application of MET Pharmacodynamic Assays to Compare Effectiveness of Five MET Inhibitors to Engage Target in Tumor Tissue 2013 ASCO
PAR Immunoassay Pharmacodynamics of Four Reported Inhibitors of Poly(ADP-ribose) Polymerase: ABT-888, AZD2281, MK-4827, and BSI-201 2011 AACR
γH2AX Immunoassay A Novel Immunoassay (ELISA) for Quantitative γH2AX Detection and Pharmacodynamic Monitoring of DNA Damage Induced by Chemotherapeutic Agents and PARP Inhibitors 2011 AACR-NCI-EORTC
CTCs
LINE-1 Methylation
CellSearch®
PCR
Investigation of 5-fluorodeoxycytidine with Tetrahydrouridine as a Demethylation Regimen in Solid Tumors 2011 AACR-NCI-EORTC
HIF1α Immunoassay Validation and Fitness Testing of a Quantitative Immunoassay for HIF1α in Biopsy Specimens 2011 AACR-NCI-EORTC
MET Immunoassay Development and Validation of Biomarker Assays to Assess Pharmacodynamic Modulation of MET 2011 ASCO

Please email any questions or comments to PDinfo@mail.nih.gov.